Organigram is trading at a significant discount to its tangible book value, indicating potential undervaluation. The company's strong financial position, with no debt and a high cash balance, is further bolstered by investment from British American Tobacco. Analysts' projections of significant revenue and EBITDA growth in FY25 and FY26 suggest a positive outlook, making the stock an attractive buy.